May 18, 2022
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Chimerix announces sale of brincidofovir to Emergent BioSolutions

TOKYO, Japan, May 17, 2022 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio" or“the Company”) today announced that Chimerix, Inc. (Headquarters: Durham, North Carolina,"Chimerix") announced in a press release dated May 16, 2022 (EST) that Chimerix has entered into a
definitive agreement with Emergent BioSolutions Inc. (Headquarters: Gaithersburg, Maryland,"Emergent") to acquire Chimerix’s exclusive worldwide rights for the antiviral drug brincidofovir("BCV").
Please refer to Chimerix website for details of the press release.
https://ir.chimerix.com/press-releases
SymBio's exclusive worldwide license to develop, manufacture, and commercialize BCV from Chimerix
in September 2019 for all indications except the prevention and treatment of orthopox infections will
be assigned from Chimerix to Emergent but will not be affected otherwise by the aforementioned
acquisition. The Company is currently conducting global clinical trials of BCV injection for adenovirus(AdV) infection after hematopoietic stem cell transplantation and preparing for global clinical trials for
BK virus infection after renal transplantation. In addition, the Company is aiming to expand themarket and maximize the business value of BCV and initiated a joint study with Brown University in
the U.S. in March 2022 to investigate the anti-tumor effect of BCV on cytomegalovirus-associatedglioblastoma (GBM).
The Company does not expect the information presented herein to have any material impact on its
financial outlook for the fiscal year ending December 2022.

1

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125
About Anti-viral Drug Brincidofovir
Brincidofovir (BCV) is a lipid conjugate of cidofovir (CDV). CDV is an antiviral drug already approved
and marketed in the United States and the European Union, but unapproved in Japan. As BCV
exhibits not only higher anti-viral activity, but also a superior safety profile in comparison with CDV,
BCV is expected to be an effective treatment against a wide spectrum of dsDNA viruses such as
herpesviruses such as cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV) and BKvirus, papillomavirus. Moreover, BCV is an easy-to-use and novel highly active antimultiviral agent
that can reduce the risk of nephrotoxicity, which is a serious side effect of CDV. SymBio entered into
an exclusive global license agreement with Chimerix Inc. (Headquarters: Durham, NC, "Chimerix")for brincidofovir (BCV) on September 30, 2019. Under the terms of the agreement, Chimerix grants
SymBio exclusive worldwide rights to develop, manufacture, and commercialize BCV in all humanindications, excluding the prevention and treatment of orthopox infections (which includes smallpox
and monkeypox).
About Chimerix
Chimerix is a development-stage biopharmaceutical company dedicated to accelerating theadvancement of innovative medicines that make a meaningful impact in the lives of patients livingwith cancer and other serious diseases. The Company’s most advanced clinical-stage development
program , ONC201, is in development for H3 K27M-mutant glioma. For further information, please
visit the Chimerix website, www.chimerix.com
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. (NYSE: EBS) is a pharmaceutical company based in Gaithersburg,Maryland, USA. Through its pipeline of innovative vaccines and therapeutics, Emergent develops,manufactures, and distributes products worldwide to protect against public health threats.
For more information, visit Emergent website at https://www.emergentbiosolutions.com).
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who
previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen
Japan. In May 2016, the Company incorporated its wholly-owned subsidiary in the U.S., SymBio
Pharma USA, Inc. (Headquarters: Durham, North Carolina, President: Mr. Fuminori Yoshida).
The Company’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to bea leading global specialty biopharmaceutical company dedicated to addressing underserved medicalneeds.
2